GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.

AI in Healthcare, Alzheimer's Research, FDA Compliance, Insomnia Corey Hubbafd AI in Healthcare, Alzheimer's Research, FDA Compliance, Insomnia Corey Hubbafd

Why We Can't Sleep in Early Alzheimer's: The New Science of Brain Inflammation

For years, we have known that people with early-stage Alzheimer’s often struggle to get a good night's rest. For a long time, scientists thought this was simply because of "plaques"—sticky protein buildups called amyloid—clogging up the brain.

Read More
AI in Healthcare, Brain Health & Neuroscience, Clinical Trial Operations, FDA Compliance Corey Hubbafd AI in Healthcare, Brain Health & Neuroscience, Clinical Trial Operations, FDA Compliance Corey Hubbafd

Lecanemab Real-World Safety: Duke Health Study Insights for Alzheimer’s Patients

For decades, the search for a way to slow down Alzheimer’s disease felt like chasing a horizon that never got closer. However, the arrival of anti-amyloid therapies like lecanemab has shifted the conversation from "what if" to "how." While clinical trials provide a controlled environment to test these drugs

Read More
FDA, Therapuetics, Future Medicine, Big Pharma, AI in Healthcare Corey Hubbafd FDA, Therapuetics, Future Medicine, Big Pharma, AI in Healthcare Corey Hubbafd

The Role of AI in Therapeutic Drug Research and Development: Benefits and Challenges

Artificial intelligence (AI) has emerged as a transformative technology across various sectors, and its potential impact on therapeutic drug research and development is significant. By leveraging AI algorithms and machine learning, researchers can potentially accelerate the drug discovery process, identify promising drug candidates, and optimize treatment strategies. However, the integration of AI

Read More